FIELD: chemistry.
SUBSTANCE: invention relates to field of organic chemistry, namely to novel heterocyclic compounds of general formula 
(I) or to their pharmaceutically acceptable salts, where X1 stands for N and X2, X3 and X4 stand for CR5; or X1 and X2 stand for N and X3 and X4 stand for CR5; or X1, X2 and X4 stand for CR5, and X3 stands for N; or X1, X2, X3 and X4 stand for CR5; R1 stands for (a) heteroaryl radical, selected from the group, including pyridinyl, 2-oxo-1,2-dihydropyridin-3-yl, 2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl, said heteroaryl optionally contains as substituents halogen, C1-C6-alkyl, C1-C6-hydroxyalkyl, C1-C3-alkoxy-C1-C3-alkyl, C1-C6-alkoxygroup, or (b) heterocyclic radical, selected from the group, including 2-oxotetrahydropyrimidin-1-yl, 2,6-dioxotetrahydropyrimidin-1-yl, 2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl and 2,4-dioxotetrahydropyrimidin-1-yl; R2 stands for hydrogen or C1-C6-alkoxygroup; R3 stands for (a) phenyl, (b) pyridine, where said phenyl or said pyridine independently optionally contain 1-3 substituents, selected from the group, including halogen, (CH2)nNRcRd, or (c) NRaRb, (d) hydrogen, (e) halogen; Ra and Rb together with nitrogen atom, which they are bound to, form cyclic amine, containing from 3 to 5 carbon atoms, independently substituted with group (CH2)nNReRf; Rc and Rd independently stand for hydrogen, SO2R8, where R8 stands for C1-C6-alkyl; Re and Rf independently stand for hydrogen, SO2R8, where R8 stands for C1-C6-alkyl; R4 stands for CF3, CH2CF3 or CR4aR4bR4c, where (i) R4a, R4b and R4c are independently selected from the group, including C1-C3-alkyl, CD3; or (ii) taken together R4a and R4b form C2-C4-alkylene and R4c stands for cyanogroup or C1-C2-fluoroalkyl; R5 in each case independently stands for hydrogen, halogen, C1-C6-alkoxygroup or C1-C6-alkyl; n in each case independently equals 0-3. Invention also related to method of treating infection with hepatitis C virus, method of inhibiting HCV replication, application of formula (I) compound and based on it pharmaceutical composition.
EFFECT: novel heterocyclic compounds of formula (I), possessing useful biological activity are obtained.
24 cl, 3 tbl, 43 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIVIRAL HETEROCYCLIC COMPOUNDS | 2011 |
|
RU2572558C2 |
| DERIVATIVES OF (4-METHYLSULPHONYLAMINOPHENYL)-QUINOLINE, USEFUL IN TREATMENT OF HEPATITIS C | 2011 |
|
RU2572835C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| BENZOXAZEPINE PI3 INHIBITORS AND METHODS OF USE | 2010 |
|
RU2654068C1 |
| FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
| IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2678305C1 |
| CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
| BENZOXAZEPINE PI3K INHIBITORS AND METHODS OF USE | 2010 |
|
RU2600927C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2010 |
|
RU2542585C2 |
| NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2801190C2 |
